Milrinone Lactate Injection - Product Information
|Manufacture:||Fresenius Kabi USA, LLC|
|Condition:||Heart Failure (Congestive Heart Failure)|
|Form:||Liquid solution, Intravenous (IV)|
Action and Clinical Pharmacology
Milrinone Lactate Injection is a positive inotrope and vasodilator, with little chronotropic activity, different in structure and mode of action from either the digitalis glycosides or catecholamines.
Milrinone, at relevant inotropic and vasorelaxant concentrations, is a selective inhibitor of peak III cAMP phosphodiesterase isozyme in cardiac and vascular muscle. This inhibitory action is consistent with cAMP-mediated increases in intracellular ionized calcium and contractile force in cardiac muscle, as well as with cAMP-dependent contractile protein phosphorylation and relaxation in vascular muscle. Additional experimental evidence also indicates that it is not a beta-adrenergic agonist, nor does it inhibit sodium-potassium adenosine triphosphatase activity as do the digitalis glycosides.
Clinical studies in patients with congestive heart failure have shown that Milrinone Lactate Injection produces dose and plasma level-related increase in left ventricular dP/dt, increase in forearm blood flow indicating a direct arterial vasodilator activity of the drug, and improves diastolic function as evidenced by improvement in left ventricular diastolic relaxation.
Studies in normal subjects have shown that Milrinone Lactate Injection produces increases in the slope of the left ventricular pressure-dimension relationship, indicating a direct inotropic effect of the drug. Both the inotropic and vasodilatory effects have been observed over the therapeutic range of milrinone plasma concentrations of 100 - 300 ng/mL.
Following intravenous loading injections of 12.5 to 125.0 µg/kg to congestive heart failure patients, intravenous milrinone had a volume of distribution of 0.38 L/kg, a mean terminal elimination half-life of 2.3 hours, and a clearance of 0.13 L/kg/hr. Following intravenous infusions of 0.20 to 0.70 µg/kg/min to congestive heart failure patients, the drug had a volume of distribution of about 0.45 L/kg, a mean terminal elimination half-life of 2.4 hours, and a clearance of 0.14 L/kg/hr. These pharmacokinetic parameters were not dose-dependent, while the area under the plasma concentration versus time curve following loading injections was significantly dose-dependent.
The steady-state milrinone plasma levels after approximately 6 - 12 hours of unchanging maintenance infusion of 0.50 µg/kg/min are approximately 200 ng/mL.
Milrinone has been shown (by ultracentrifugation) to be in excess of 70% bound to human plasma proteins at plasma concentrations of 70 - 400 ng/mL.
The primary route of excretion of milrinone in man is via the urine, with much smaller amounts recovered in the feces. The major urinary excretion products in man are milrinone (83%) and its O-glucuronide metabolite (12%). Elimination in normal subjects via the urine is rapid, with approximately 60% recovered within the first two hours following dosing, and approximately 90% recovered within the first eight hours following dosing. The mean renal clearance of milrinone is approximately 0.3 L/min while that of the metabolites is even greater, indicative of active secretion.
In patients with moderate to severe renal impairment, both Cmax (210 ng/mL) and tmax (1.19 hr) were increased compared to subjects with normal renal function (162 ng/mL and 0.64 hr, respectively). The half-life of milrinone increased from 0.94 hr in subjects with normal renal function to 1.71 hr in patients with moderate renal impairment and to 3.09 hr in patients with severe renal impairment.
In patients with congestive heart failure, intravenous milrinone produces prompt, significant improvements in cardiac output, pulmonary capillary wedge pressure and vascular resistance without clinically significant increases in heart rate or myocardial oxygen consumption. Onset of action generally occurs within 5 to 15 minutes.
Improvement in left ventricular function and relief of congestive heart failure symptoms in patients with ischemic heart disease have been observed. The improvement has occurred without inducing symptoms or electrocardiographic signs of myocardial ischemia.
In studies in congestive heart failure patients, Milrinone Lactate Injection administered as a loading injection followed by a maintenance infusion produced the following pharmacodynamic changes:
|Loading Dose||Maintenance Infusion||CI||PCWP||SVR||HR||MAP|
Patients evaluated for 48 hours maintained improvements in hemodynamic function, with no evidence of diminished response (tachyphylaxis), and in a small number of patients no evidence of tachyphylaxis was seen for as long as 72 hours of infusion.
The duration of therapy should depend upon patient responsiveness. Patients have been maintained on infusion of milrinone up to five days.
Intravenous milrinone is effective in fully digitalized patients without affecting glycoside plasma levels.
Milrinone has been shown to enhance atrio-ventricular nodal conduction rate (see Precautions).
Indications and Clinical Use
Milrinone Lactate Injection is indicated for the short-term management of severe congestive heart failure including low output states following cardiac surgery. The majority of experience with the drug has been in patients receiving digoxin and diuretics. In some patients, Milrinone Lactate Injection has been shown to increase ventricular ectopy (see Warnings).
Milrinone Lactate Injection is contraindicated in patients who are hypersensitive to it or to any of its ingredients.
Supraventricular and ventricular arrhythmias have been observed in the high risk population of congestive heart failure patients treated with Milrinone Lactate Injection. In using the drug, consideration should be given to the fact that in some patients, Milrinone Lactate Injection has been associated with an increase in ventricular ectopy including ventricular tachycardia or fibrillation (see Adverse Reactions). The incidence of arrhythmias has not been shown to be related to the dose or plasma level of milrinone. Patients receiving Milrinone Lactate Injection should be closely monitored during infusion.
No clinical studies have been conducted in patients in the acute phase of post myocardial infarction. Until further clinical experience is gained, milrinone is not recommended in these patients.
Milrinone Lactate Injection should not be used in lieu of surgical relief of the obstruction in patients with severe obstructive aortic or pulmonic valvular disease. Like other inotropic agents, it may aggravate outflow tract obstruction in hypertrophic subaortic stenosis.
Milrinone Lactate Injection has been shown to enhance AV nodal conduction rate, indicating a potential for an increased ventricular response rate in patients with atrial flutter/fibrillation which is not being controlled with digitalis therapy. Digitalisation of these patients should be considered prior to the administration of milrinone.
During therapy with Milrinone Lactate Injection, blood pressure and heart rate should be monitored and the rate of infusion slowed or stopped in patients showing excessive decrease in blood pressure.
Patients who have received vigorous diuretic therapy may have insufficient cardiac filling pressure to respond adequately to Milrinone Lactate Injection, in which case cautious liberalization of fluid and electrolyte intake may be indicated.
Fluid and electrolyte changes and renal function should be carefully monitored during therapy with Milrinone Lactate Injection.
Improvement in cardiac output with resultant diuresis may necessitate a reduction in the dose of diuretic. Potassium loss due to excessive diuresis may predispose digitalized patients to arrhythmias. Therefore, hypokalemia should be corrected by potassium supplementation in advance of or during milrinone administration.
Use in Renally Impaired Patients
Data obtained from patients with severe renal impairment (creatinine clearance = 0 - 30 mL/min) but without congestive heart failure have demonstrated that the presence of renal impairment significantly increases the terminal elimination half-life of milrinone. Reductions in the infusion rate may be necessary in patients with renal impairment (see Dosage and Administration).
Use in Elderly Patients
Experience so far suggests that no special dosage recommendations for the elderly patient are necessary.
Use in Pregnancy
Milrinone did not appear to be teratogenic when administered intravenously to pregnant rats at doses up to 3 mg/kg/day or pregnant rabbits at doses up to 12 mg/kg/day, although an increase in resorption rate was apparent at both 8 and 12 mg/kg/day (intravenous) in the latter species.
There are no studies in pregnant women. Milrinone Lactate Injection should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Use in Nursing Mothers
Caution should be exercised when Milrinone Lactate Injection is administered to nursing women, since it is not known whether it is excreted in human milk.
Use in Children
Safety and effectiveness in children have not been established.
No untoward clinical manifestations have been observed in patients in whom Milrinone Lactate Injection was used concurrently with the following drugs: digitalis glycosides, lidocaine, quinidine, hydralazine, prazosin, isosorbide dinitrate, nitroglycerin, chlorthalidone, furosemide, hydrochlorothiazide, spironolactone, captopril, heparin, warfarin, diazepam, insulin, and potassium supplements.
Precipitation occurs immediately when furosemide is mixed with milrinone solution. Therefore, furosemide should not be administered in intravenous lines containing Milrinone Lactate Injection.
Other drugs should not be mixed with Milrinone Lactate Injection until further compatibility data are available.
Oral and intravenous administration of toxic dosages of milrinone to rats and dogs resulted in myocardial degeneration/fibrosis and endocardial hemorrhage, principally affecting the left ventricular papillary muscles. Coronary vascular lesions characterized by periarterial edema and inflammation have been observed in dogs only. The myocardial/endocardial changes are similar to those produced by beta-adrenergic receptor agonists such as isoproterenol, while the vascular changes are similar to those produced by minoxidil and hydralazine. Doses within the recommended clinical dose range (up to 1.13 mg/kg/day) for congestive heart failure patients have not produced significant adverse effects in animals.
In clinical trials involving 413 patients who received Milrinone Lactate Injection, the most frequent adverse effects observed were ventricular arrhythmias (12.6%) and the most severe adverse effect observed was ventricular fibrillation (0.2%).
Adverse reactions occurring in patients treated with Milrinone Lactate Injection are shown below in order of decreasing frequency:
|Ventricular ectopic activity||9.0%|
|Angina pectoris/Chest pain||1.4%|
Symptoms and Treatment of Overdosage
No specific antidote to milrinone is known, but general measures for circulatory support should be taken. Milrinone Lactate Injection may produce hypotension because of its vasodilator effect. In case of overdose, administration of Milrinone Lactate Injection should be reduced or temporarily discontinued until the patient's condition stabilizes.
Dosage and Administration
- Prior correction or adjustment of fluid/electrolytes may be necessary to obtain a satisfactory response with Milrinone Lactate Injection (see Precautions).
- Suitable diluents include Normal or Half Normal Saline Injection or sterile 5% Dextrose Injection.
- Diluted solutions should be used within 24 hours at room temperature or within 72 hours if refrigerated (2 °C − 8 °C).
- Furosemide should not be added to Milrinone Lactate Injection due to a chemical interaction.
Milrinone Lactate Injection should be administered with a loading dose followed by a continuous infusion (maintenance dose) according to the following guidelines:
|50 µg/kg: administered slowly over 10 minutes
(For ease of administration, Milrinone Lactate Injection may be diluted with suitable diluents or used undiluted if suitable infusion equipment is available.)
|Infusion Rate||Total Daily Dose|
|Administer as a continuous intravenous infusion|
The infusion rate should be adjusted according to hemodynamic and clinical response. Patients should be closely monitored. In controlled clinical studies, most patients showed an improvement in hemodynamic status as evidenced by increases in cardiac output and reduction in pulmonary capillary wedge pressure. Dosage may be titrated to the maximum hemodynamic effect but should not exceed 1.13 mg/kg/day. Duration of therapy should depend upon patient responsiveness.
Intravenous infusions of Milrinone Lactate Injection should be administered as described in the following chart.
|Milirinone Lactate||Concentration of Milrinone in Infusion|
|Dosage (μg/kg/min)||100 μg/mL*||150 μg/mL**||200 μg/mL†|
In order to calculate flow rate (mL/hr), multiply infusion delivery rate by patient weight in kilograms.
*Prepare by adding 180 mL diluent per 20 mg vial (20 mL) Milrinone Lactate Injection.
**Prepare by adding 113 mL diluent per 20 mg vial (20 mL) Milrinone Lactate Injection.
† Prepare by adding 80 mL diluent per 20 mg vial (20 mL) Milrinone Lactate Injection.
Dosage Adjustment in Renally Impaired Patients
The loading dosage is not affected, but reductions in the maintenance infusion rate may be necessary according to the following table. (See Precautions, Use in Renally Impaired Patients).
|Creatinine||Milrinone Lactate||Concentration of Milrinone in Infusion|
|(mL/min/1.73 m2)||(μg/kg/min)||100 μg/mL*||150 μg/mL**||200 μg/mL†|
In order to calculate flow rate (mL/hr), multiply infusion delivery rate by patient weight in kilograms.